UY31417A1 - A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION - Google Patents

A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION

Info

Publication number
UY31417A1
UY31417A1 UY31417A UY31417A UY31417A1 UY 31417 A1 UY31417 A1 UY 31417A1 UY 31417 A UY31417 A UY 31417A UY 31417 A UY31417 A UY 31417A UY 31417 A1 UY31417 A1 UY 31417A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
polytherapy
pimecrolimus
everolimus
sirolimus
Prior art date
Application number
UY31417A
Other languages
Spanish (es)
Inventor
Rolando Perez Rodriguez
Ramkrishnan Melarkode
Pradip Nair
Jose Enrique Montero Casimiro
Indira Venkata Chivukula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31417A1 publication Critical patent/UY31417A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una politerapia, de un agente inhibidor de EGFR que inhibe competitivamente la union del EGF natural al receptor y al inmunosupresor para tratar a un huésped mamífero, preferiblemente humano por administracion de una concentracion terapéuticamente efectiva de un fármaco para la prevencion y/o tratamiento de tumores. Los agentes inmunosupresores preferidos pueden seleccionarse del grupo de sirolimus, tacrolimus, everolimus, pimecrolimus en forma libre o en forma de sal farmacéuticamente aceptable.A polytherapy of an EGFR inhibitor agent that competitively inhibits the binding of natural EGF to the receptor and the immunosuppressant to treat a mammalian host, preferably human by administration of a therapeutically effective concentration of a drug for prevention and / or treatment is described of tumors Preferred immunosuppressive agents may be selected from the group of sirolimus, tacrolimus, everolimus, pimecrolimus in free form or in the form of a pharmaceutically acceptable salt.

UY31417A 2007-10-22 2008-10-22 A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION UY31417A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2373CH2007 2007-10-22

Publications (1)

Publication Number Publication Date
UY31417A1 true UY31417A1 (en) 2009-05-29

Family

ID=40579132

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31417A UY31417A1 (en) 2007-10-22 2008-10-22 A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION

Country Status (5)

Country Link
AR (1) AR072759A1 (en)
CU (1) CU23798B6 (en)
TW (1) TW200942260A (en)
UY (1) UY31417A1 (en)
WO (1) WO2009054001A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
PL216224B1 (en) * 2002-02-01 2014-03-31 Ariad Pharmaceuticals Phosphorus-containing compounds and uses thereof
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
BRPI0510883B8 (en) * 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
AU2006311877A1 (en) * 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
WO2007059782A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007106503A2 (en) * 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors

Also Published As

Publication number Publication date
CU23798B6 (en) 2012-03-15
AR072759A1 (en) 2010-09-22
CU20090007A6 (en) 2011-07-11
WO2009054001A1 (en) 2009-04-30
TW200942260A (en) 2009-10-16

Similar Documents

Publication Publication Date Title
UY31417A1 (en) A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR SUCH PHARMACEUTICAL COMPOSITION
MX2021002886A (en) Combination therapy for the treatment of triple-negative breast cancer.
Freret et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice
EA200970932A1 (en) METHODS OF TREATMENT WITH THE APPLICATION OF PYRIDOPYRIMIDINONOVES INHIBITORS PI3K ALPHA
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
RU2008124827A (en) TREATMENT OF NEUROENDOCRINE TUMORS
WO2008050329A3 (en) Novel sirnas and methods of use thereof
AR072442A1 (en) METHOD FOR CANCER THERAPY, USE, KIT
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
RS54707B1 (en) Treatment of crohn's disease with laquinimod
ATE551060T1 (en) COMPOSITIONS AND METHODS FOR TREATING NEOVASCULAR DISEASES
CL2007001554A1 (en) Compounds derived from pyrido [3,2-e] pyrazines; pde10 inhibitors; preparation process; pharmaceutical composition comprising; pharmaceutical kit; Use to prepare a medication to treat or prevent disorders associated with the hyperactivity of pde10 and / or disorders in which inhibiting pde10 is of value.
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CO6630082A2 (en) Lupus nephritis treatment using laquinimod
ECSP088762A (en) PAIN TREATMENT
EA200970928A1 (en) ANTAGONISTS OF THE GONADOTROPIN-RILIZIN-FACTOR RECEPTOR AND METHODS OF THEIR USE
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
AR062658A1 (en) COMBINATION THERAPIES FOR REUMATOID ARTHRITIS
AR074240A1 (en) COMPOUND 3- (4-CHLORO-2-FLUOROBENCIL) -2-METHYL-N- (5- METHYL-1H- PIRAZOL-3-IL) -8- (MORFOLINOMETIL) IMIDAZO (1,2-B) PIRIDAZIN -6- AMINA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC MYELOPROLIFERANT DISORDERS AND ASOCI CONDITIONS
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
UY33221A (en) METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS
BRPI0511800A (en) irinotecan treatment (cpt-11) and an egfr inhibitor
BR112017007239A2 (en) aurora kinase inhibitor, its uses, and pharmaceutical composition ".
ATE543492T1 (en) TREATMENT OF LUNG CANCER

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171017